AR083747A1 - Anticuerpos anti-il-23 - Google Patents
Anticuerpos anti-il-23Info
- Publication number
- AR083747A1 AR083747A1 ARP110104094A ARP110104094A AR083747A1 AR 083747 A1 AR083747 A1 AR 083747A1 AR P110104094 A ARP110104094 A AR P110104094A AR P110104094 A ARP110104094 A AR P110104094A AR 083747 A1 AR083747 A1 AR 083747A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr1
- cdr2
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41015810P | 2010-11-04 | 2010-11-04 | |
| US41195310P | 2010-11-10 | 2010-11-10 | |
| US41259410P | 2010-11-11 | 2010-11-11 | |
| US201161448785P | 2011-03-03 | 2011-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083747A1 true AR083747A1 (es) | 2013-03-20 |
Family
ID=44936573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104094A AR083747A1 (es) | 2010-11-04 | 2011-11-03 | Anticuerpos anti-il-23 |
Country Status (39)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| PL2635601T3 (pl) | 2010-11-04 | 2017-02-28 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23 |
| PL3326649T3 (pl) * | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| JOP20140049B1 (ar) * | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| EP3689369A1 (en) | 2013-03-15 | 2020-08-05 | Amgen, Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| SG10201805015TA (en) | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| EA039598B9 (ru) * | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
| KR20240158362A (ko) * | 2015-02-04 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| CA2977534A1 (en) | 2015-04-14 | 2016-10-20 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
| TWI733685B (zh) | 2015-07-23 | 2021-07-21 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向il-23a與b細胞活化因子(baff)之化合物及其用途 |
| WO2017049035A1 (en) * | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| TWI733695B (zh) * | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| RS63125B1 (sr) * | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
| BR112018012626A2 (pt) | 2015-12-22 | 2018-12-04 | Amgen Inc | ccl20 como um preditor de resposta clínica a antagonistas de il23 |
| EP4410997A3 (en) | 2016-04-15 | 2024-11-13 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
| JP2019536756A (ja) | 2016-10-14 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２３ａ抗体を用いて疾患を処置する方法 |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR20200118117A (ko) * | 2018-02-05 | 2020-10-14 | 테사로, 인코포레이티드 | 소아용 니라파립 제제 및 소아용 치료 방법 |
| TWI744617B (zh) | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| KR20210032441A (ko) | 2018-07-13 | 2021-03-24 | 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 | 브라지쿠맙을 이용한 궤양성 대장염의 치료 |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
| EP3956357A4 (en) * | 2019-04-15 | 2023-01-04 | Sun Pharmaceutical Industries Limited | METHODS OF TREATMENT OF SUBJECTS WITH PSORIAL ARTHRITIS |
| TW202123965A (zh) * | 2019-09-09 | 2021-07-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| AU2020409124A1 (en) * | 2019-12-20 | 2022-06-30 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
| TW202428304A (zh) | 2020-09-10 | 2024-07-16 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
| TW202231292A (zh) | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法 |
| CA3219846A1 (en) | 2021-05-28 | 2022-12-01 | Venkatesh Krishnan | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
| KR102761841B1 (ko) | 2021-07-09 | 2025-02-05 | 연세대학교 산학협력단 | Il-23에 의해 매개되는 질환의 중증도 예측용 조성물 |
| WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
| WO2024085697A1 (en) | 2022-10-21 | 2024-04-25 | Chong Kun Dang Pharmaceutical Corp. | Stable antibody composition |
| KR20250152080A (ko) | 2023-02-22 | 2025-10-22 | 일라이 릴리 앤드 캄파니 | 궤양성 결장염에서의 유전자의 조절 및 그의 용도 |
| WO2024263900A2 (en) * | 2023-06-22 | 2024-12-26 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| WO2025117506A1 (en) | 2023-11-29 | 2025-06-05 | Gilead Sciences, Inc. | Therapies for the treatment of inflammatory bowel disease |
| WO2025170982A2 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025171006A1 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| CN117875575B (zh) * | 2024-03-12 | 2024-05-28 | 中国电子科技集团公司第二十九研究所 | 一种基于混合仿生算法的干扰资源分配方法 |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ZA936128B (en) | 1992-08-21 | 1995-02-20 | Genentech Inc | Method for treating a LFA-1 mediated disorder |
| EP0669836B1 (en) | 1992-11-13 | 1996-07-03 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| AU2661199A (en) | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| DE69942607D1 (de) | 1998-04-14 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| CN100529076C (zh) | 1999-09-09 | 2009-08-19 | 先灵公司 | 哺乳动物细胞因子、相关试剂和方法 |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| EP1918377B1 (en) | 2000-05-10 | 2013-12-04 | Merck Sharp & Dohme Corp. | Mammalian cytokine receptor subunit proteins, related reagents and methods |
| JPWO2003034818A1 (ja) | 2001-10-24 | 2005-02-10 | 中外製薬株式会社 | Ｓｇｒｆ遺伝子改変非ヒト動物 |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| NZ539271A (en) | 2002-10-30 | 2008-12-24 | Genentech Inc | Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23) |
| JP4902961B2 (ja) | 2002-12-23 | 2012-03-21 | シェーリング コーポレイション | 哺乳動物サイトカインの用途；関連試薬 |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| NZ541898A (en) | 2003-03-10 | 2008-07-31 | Schering Corp | Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors |
| WO2005005612A2 (en) | 2003-07-01 | 2005-01-20 | University Of Virginia Patent Foundation | Tag-1 and tag-2 proteins and uses thereof |
| DK2149585T3 (da) | 2003-11-04 | 2013-10-21 | Novartis Vaccines & Diagnostic | Anvendelse af antagonistiske anti-CD40-monoklonale antistoffer |
| EP1684805B8 (en) | 2003-11-04 | 2010-08-25 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| AU2005215527B2 (en) | 2004-02-17 | 2011-04-07 | Merck Sharp & Dohme Corp. | Methods of modulating IL-23 activity; related reagents |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| BRPI0510617A (pt) | 2004-05-03 | 2007-10-30 | Schering Corp | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento |
| CA2581505A1 (en) * | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI363091B (en) | 2004-12-20 | 2012-05-01 | Schering Corp | Uses of mammalian cytokine; related reagents |
| CA2612785A1 (en) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Polynucleotides and polypeptides of the il-12 family of cytokines |
| HUE042561T2 (hu) | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások |
| DK1937721T3 (da) | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
| CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
| ES2619845T3 (es) * | 2005-08-31 | 2017-06-27 | Merck Sharp & Dohme Corp. | Anticuerpos anti-IL-23 diseñados por ingeniería genética |
| NZ566424A (en) | 2005-09-01 | 2011-10-28 | Schering Corp | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
| AU2006330410A1 (en) | 2005-12-28 | 2007-07-05 | Centocor, Inc. | Markers and methods for assessing and treating psoriasis and related disorders |
| ES2807928T3 (es) | 2005-12-29 | 2021-02-24 | Janssen Biotech Inc | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20080031882A1 (en) | 2006-06-19 | 2008-02-07 | Liang Spencer C | Methods of modulating IL-22 and IL-17 |
| CL2008000058A1 (es) | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| AU2008216090A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein formulations containing sorbitol |
| EP2064242A1 (en) | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| AR065420A1 (es) | 2007-02-23 | 2009-06-03 | Schering Corp | Anticuerpos anti-il-23 p19 de ingenieria |
| CN101668531B (zh) | 2007-02-28 | 2014-05-07 | 默沙东公司 | 用于治疗免疫病症的联合治疗 |
| EP2197903B9 (en) | 2007-09-04 | 2015-04-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| EP2212442A1 (en) | 2007-10-26 | 2010-08-04 | Galderma Research & Development | Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof |
| CA2607771A1 (en) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
| KR20190045414A (ko) | 2007-11-30 | 2019-05-02 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US8563697B2 (en) | 2008-08-14 | 2013-10-22 | Cephalon Australia Pty. Ltd. | Anti-IL-12/IL-23 antibodies |
| EP2331078B1 (en) | 2008-08-27 | 2012-09-19 | Merck Sharp & Dohme Corp. | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US20120128689A1 (en) | 2009-04-01 | 2012-05-24 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| EP2414546A4 (en) | 2009-04-02 | 2013-03-13 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASE AND COLON CARCINOMA |
| US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US20120294852A1 (en) | 2009-11-24 | 2012-11-22 | Smith Jeffrey T L | Antagonists of il-6 to raise albumin and/or lower crp |
| EP2506785A4 (en) | 2009-12-02 | 2014-10-15 | Spartek Medical Inc | LOW PROFILE SPINAL PROSTHESIS WITH A BONE ANCHOR WITH A HINGED BAR AND A VERTICAL TOWER ROD |
| GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| JP2013520426A (ja) | 2010-02-18 | 2013-06-06 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質 |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR101853981B1 (ko) | 2010-03-01 | 2018-05-02 | 사이토딘 인크. | 농축 단백질 제형물 및 그의 용도 |
| WO2011159750A1 (en) | 2010-06-15 | 2011-12-22 | Celgene Corporation | Biomarkers for the treatment of psoriasis |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| NZ604415A (en) | 2010-07-20 | 2014-10-31 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| JP6173911B2 (ja) | 2010-09-10 | 2017-08-09 | メディミューン リミテド | 抗体誘導体 |
| PL2635601T3 (pl) | 2010-11-04 | 2017-02-28 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23 |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
| US9078894B2 (en) | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
| PL3326649T3 (pl) | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| SG10201805015TA (en) | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| EP3689369A1 (en) | 2013-03-15 | 2020-08-05 | Amgen, Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| EA039598B9 (ru) | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
| KR20240158362A (ko) | 2015-02-04 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| TWI733685B (zh) | 2015-07-23 | 2021-07-21 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向il-23a與b細胞活化因子(baff)之化合物及其用途 |
| TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
-
2011
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/en not_active Withdrawn
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 CA CA3017116A patent/CA3017116A1/en not_active Abandoned
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/en not_active Withdrawn
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/en active Active
- 2011-11-02 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active Active
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 PH PH1/2013/500810A patent/PH12013500810B1/en unknown
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/en not_active Ceased
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active Active
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/en not_active Withdrawn
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-02 CA CA2816950A patent/CA2816950C/en active Active
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/me unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I2/el unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en not_active Abandoned
-
2024
- 2024-03-14 US US18/605,420 patent/US20250101093A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083747A1 (es) | Anticuerpos anti-il-23 | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| AR079336A1 (es) | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
| EP3255063A3 (en) | Antibodies to matrix metalloproteinase 9 | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| ES2685823T3 (es) | Anticuerpos antagonistas anti-CD40 | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| AR073140A1 (es) | Anticuerpos anti-il-23r disenados | |
| ES2684173T3 (es) | Anticuerpos anti-XCR1 humano | |
| MX2018013176A (es) | Anticuerpos anti-basigin humanizados y el uso de los mismos. | |
| EP3103810A3 (en) | Modified variable domain molecules and methods for producing and using them | |
| NZ594452A (en) | Anti-mst1r antibodies and uses thereof | |
| AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
| AR076083A1 (es) | Anticuerpo monoclonal anti-rhesus d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |